Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy.

ABSTRACT:

Background

As neoadjuvant chemotherapy (NAC) is increasingly used in triple-negative breast cancer (TNBC), we investigated the value of circulating tumor DNA (ctDNA) for patient monitoring prior, during, and after NAC, and circulating tumor cells (CTCs) for disease characterization at clinical progression.

Materials and methods

Forty-two TNBC patients undergoing NAC were prospectively enrolled. Primary tumor mutations identified by targeted-gene sequencing were validated and tracked in 168 plasma samples longitudinally collected at multiple time-points by droplet digital polymerase chain reaction. At progression, plasma DNA underwent direct targeted-gene assay, and CTCs were collected and analyzed for copy number alterations (CNAs) by low-pass whole genome sequencing.

Res

SUBMITTER: Ortolan E 

PROVIDER: S-EPMC8010400 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature